Project Grant R43CA224512

The National Cancer Institute (NCI) awarded a $398,738 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Pre-Cancer Diagnosis, LLC to develop a highly sensitive DNA hypermethylation-based diagnostic kit to identify patients with Barrett's esophagus (BE) who are at high risk of progressing to esophageal adenocarcinoma (EAC). The grant aims to validate the company's preliminary findings on using DNA methylation biomarkers to differentiate high-risk and...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...

This $370,575 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to identify DNA methylation biomarkers for adenoid cystic carcinoma (ACC), a common salivary gland cancer. The key objectives are to: Examine DNA methylation and transcriptomic profiles of 200 clinically annotated ACC tumors to refine subtyping and prognosis. Profile methylation/transcriptome of paired primary and metastatic ACC...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $646,186 to Nord Bio Inc. to develop and evaluate an assay to detect and monitor the level of circulating free DNA (cfDNA) from tumors in saliva. The goal is to establish a reliable, non-invasive method for detecting and monitoring cancer, with a focus on head and neck squamous cell carcinoma (HNSCC). The research aims to compare the sensitivity of cfDNA detection in...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,540.00 to the Sloan-Kettering Institute for Cancer Research to investigate the use of electronic nose (e-nose) technology to predict and assess response to induction therapy and identify recurrence in patients with locally advanced non-small cell lung cancer. The research aims to evaluate volatile organic compounds in patient exhalates to improve the prediction and assessment of...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $215,985 to The Leland Stanford Junior University to conduct a pilot study on using exosome signatures as early biomarkers to predict response to immune checkpoint inhibitor therapy in metastatic renal cell carcinoma patients. The study aims to 1) define an exosome signature of response by analyzing exosomal RNA from blood and urine at baseline and 3/6 weeks after...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...

This $692,491 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop a minimally-invasive, highly sensitive blood-based test for early detection of common cancers including prostate, lung, colorectal, and ovarian. The primary goal is to investigate early epigenetic signatures in circulating cell-free DNA that could enable detection of these cancers before overt disease onset. The...

This Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The award will fund a multi-phase study to optimize, verify, and validate the GLISCAN assay, which leverages digital PCR...